⬅ # 407 Robert Rich Jr|# 409 Mark Stevens

# 408 Viktor Kharitonin 


Real Time Net Worth
as of 5/21/2024
$50 (0.00%)

# 408 Viktor Kharitonin 


Real Time Net Worth
as of 5/21/2024
$50 (0.00%)
OccupationCofounder and Chair, Pharmstandard
Source of WealthPharmaceuticals
ResidenceMoscow, Russia
Marital StatusMarried
EducationBS, Novosibirsk State University
Age-Adjusted Net Worth$12.8B
Viktor Kharitonin
Viktor Kharitonin
Net worth: $6.95B

Self-Made Score 

Wealth History

Hover or tap to reveal net worth by year
Loading Chart



Viktor Kharitonin, a Russian billionaire, co-founded Pharmstandard with Roman Abramovich in 2003, which became a multinational pharmaceutical firm.
He gained significant wealth through Pharmstandard, initially listing it on the London Stock Exchange in 2008 before privatizing it again in 2016.
He expanded his business portfolio by acquiring TSS group in 2021 through Augment Investments.
Kharitonin also owns the Nürburgring race track and is considering purchasing the Frankfurt–Hahn Airport.
Despite his wealth and business ventures, Kharitonin resides primarily in Moscow and is known to be close to Russian Deputy Prime Minister Tatyana Golikova and her husband Viktor Khristenko.

Business Ventures

Pharmstandard, a multinational pharmaceutical firm, was co-founded by Kharitonin and Roman Abramovich in 2003.
In 2008, Pharmstandard was listed on the London Stock Exchange, but Kharitonin later privatized it again in 2016.
Kharitonin and his partner Egor Kulkov acquired TSS group in 2021 through Augment Investments.
Kharitonin holds stakes in other Russian pharmaceutical companies, including OTCPharm, Biocad, and Generium, which produces the Sputnik V COVID-19 vaccine.
He has diversified his portfolio beyond pharmaceuticals by owning the Nürburgring race track in Germany and considering the purchase of the Frankfurt–Hahn Airport.
His business ventures reflect a strategic expansion into various sectors, enhancing his wealth and influence.

Sanctions and Controversies

Despite being a Russian billionaire, Kharitonin has not been sanctioned by any country other than Ukraine as of 2022.
There were allegations that Kharitonin avoided sanctions by relocating his firm, Augment Investments, from Cyprus to Oktyabrsky Island in Russia.
This relocation was purportedly facilitated by utilizing Russia's Special Economic Region scheme.
Kharitonin's avoidance of sanctions and his close ties to Russian officials have raised questions and controversies surrounding his business practices.
However, he has maintained a significant presence in the global business landscape, leveraging his connections and resources effectively.


JSC Pharmstandard is a Russian multinational pharmaceutical company headquartered in Dolgoprudny, Moscow Oblast.
Established in 2003 through a merger, Pharmstandard has become a major player in the pharmaceutical industry.
The company manufactures and exports over 400 generic and proprietary drugs, catering to various medical needs such as diabetes, cardiovascular diseases, infectious diseases, and cancer treatment.
Pharmstandard operates six manufacturing facilities across Russia, located in Moscow, Ufa, Nizhny Novgorod, Kursk, Tomsk, and Tyumen.
In May 2007, Pharmstandard raised $880 million in an IPO, valuing the company at $2.2 billion.
The company was delisted from both the London and Moscow stock exchanges in 2017.

How long would it take you to become as rich as Viktor Kharitonin?

If you started with $10,000 and invested an additional $500 each month at a 44.10% CAGR, it would take you 5 years to reach Viktor Kharitonin's net worth of $6.95B.

Is this realistic? It depends how closely the VIX-TA-Macro Advanced model performs to its history in the future. Since Grizzly Bulls launched on January 1, 2022, it's returned 42.76% compared to 11.89% for the S&P 500 benchmark.

Enter data in all but one field below, then calculate the missing value

Viktor Kharitonin is very wealthy, but what's stopping you from reaching that same level of success? As summarized in our five fundamental rules to wealth building, becoming wealthy in a modern capitalist economy is not complicated. There's actually only three variables:

  1. Your starting capital
  2. Your earnings after expenses
  3. The compound annual growth rate (CAGR) of your savings

Most people start with zero or very little, so if you weren't born into wealth, don't fret! The majority of the fortunate folks listed in our Grizzly Bulls’ Billionaires Index came from middle class or lower backgrounds. The most distinguishing characteristic of the group is their ability to consistently earn a high CAGR on their savings.

Every billionaire has a unique strategy to achieve high CAGR. For Viktor Kharitonin, Pharmaceuticals is the primary source. Whether you choose to invest your savings in your own businesses or the businesses of others is not as important. The salient piece of the puzzle is ensuring that your hard-earned savings are generating sufficient CAGR to reach your long term goals.

Most people simply invest their money in index funds and call it a day. There's nothing wrong with this approach, but it guarantees relative mediocrity. To achieve greatness, you need to invest your money to earn higher than average returns. In the long run, better investors will always finish ahead of better earners.

Source: Grizzly Bulls reporting

Methodology: Grizzly Bulls' Billionaires Index is a daily ranking of the world's billionaires and richest people. Grizzly Bulls strives to provide the most accurate net worth calculations available. We pull data from public equity markets, SEC filings, public real estate records, and other reputable sources.

The index is dynamic and updates daily at the close of U.S. stock market trading based on changes in the markets, economy, and updates to Grizzly Bulls' proprietary algorithm of personal wealth calculation. Stakes in public companies are tracked daily based on the relevant closing prices of the underlying securities. Additionally, stakes in private companies, cash, real estate, and other less easily valued assets are updated periodically through careful analysis of insider transactions, comparable public company sales / EBITDA multiples, etc.

Edited by: Lee Bailey